Azitra (AZTR)
Develops engineered skin bacteria and proteins for dermatology, cosmetic ingredients, and biotechnology tools.
Something off on this page? Send us feedback.
Develops engineered skin bacteria and bacteria-derived proteins for dermatology, skincare ingredients, and biotechnology tools, with ATR-COSF a strategic priority. Has no approved products or commercial revenue and uses third parties across its development and manufacturing chain.
Builds skin-focused products around engineered commensal bacteria, bacteria-derived proteins, and a microbial library. The platform combines strain screening, genetic engineering, and machine-learning-assisted molecule discovery for therapeutic dermatology, ATR-COSF cosmetic ingredients, and recombinant biotechnology products.
Operates from Connecticut with research activity in Canada, using academic collaborators, contract research organizations, and contract manufacturers. A clinical candidate for cancer-therapy-related rash remains under study, while Netherton syndrome enrollment is paused and ATR-COSF has ex vivo human-skin evidence. Has no approved products or commercial revenue and lacks commercial-scale manufacturing facilities; development, clinical supply, and future manufacture depend on third parties.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $6.7M · Total debt $410.1K · Total assets $8.9M · Shareholders' equity $7.3M
- Revenue
- $0
- Operating income
- −$3.4M
- Net income
- −$3.3M
No dividends on record.
| Institutions7 holders · as of Mar 31, 2026 | 0.89% | 540.5K shares | |
| Insiders1 holder · as of Jun 24, 2026 | 8.95% | 5.42M shares | |
| Otherremainder | 90.16% | 54.64M shares |
60.60M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (60.60M in the company's Sep 3, 2026 report, 10.74M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Nantahala Capital Management, LLCInstitution | 10.69% | 6.48M | 13Gfiled Aug 14, 2026 ↗ |
Nantahala Capital Partners Limited PartnershipInstitution | 8.99% | 5.45M | 13Gfiled Aug 14, 2026 ↗ |
Salva Francisco D.Insider | 8.95% | 5.42M | 13Dfiled Jun 24, 2026 ↗ |
Geode Capital Management, LLCInstitution | 0.78% | 469,878 | 13Fas of Mar 31, 2026 |
UBS Group AGInstitution | 0.05% | 30,205 | 13Fas of Mar 31, 2026 |
| See all 19 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
- Quoin Pharmaceuticals (ADR)
Late-stage topical therapy for Netherton syndrome.
- Thermo Fisher Scientific
Commercial T7 RNA polymerase and TEV protease for research labs.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Azitra | $0.1826 | +3.99% | $1.9M | — | — | — | — |
| Quoin Pharmaceuticals (ADR) | $6.57 | −3.50% | $13.5M | — | — | — | — |
| Thermo Fisher Scientific | $610.02 | +0.26% | $226.15B | 32.7 | 23.2 | 4.9 | +10.5% |
| Median | 32.7 | 23.2 | 4.9 | +10.5% |